| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$7.8M | ROE | −950.12% |
| Net Margin | — | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
| Market Cap | $180.0M | Trading Days | 2500 |
| 52W High | 2.38 |
| 52W Low | 0.75 |
| % Off High | −67.16% |
| YTD | −37.48% | 1Y | −65.87% |
| 3Y | −94.66% | 5Y | −98.48% |
| 10Y | −95.53% | Since incept. (ann.) | −27.16% |
| Ann. Volatility (1Y) | 80.93% | Ann. Volatility (3Y) | 142.47% |
| Sharpe (1Y) | −0.96 | Sharpe (3Y) | −0.16 |
| Max Drawdown (1Y) | −65.87% | Max Drawdown (3Y) | −95.11% |
| Beta (3Y, vs SPY) | 0.85 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| ALGS | Aligos Therapeutics, Inc. | $181.1M | — |
| ACOG | Alpha Cognition Inc. | $183.1M | — |
| VYGR | Voyager Therapeutics, Inc. | $183.7M | — |
| LENZ | LENZ Therapeutics, Inc. | $184.4M | — |
| DTIL | PRECISION BIOSCIENCES INC | $185.0M | — |
| IVVD | Invivyd, Inc. | $174.8M | — |
| PLX | Protalix BioTherapeutics, Inc. | $187.7M | — |
| CRIS | CURIS INC | $188.3M | — |
| ALEC | Alector, Inc. | $168.8M | — |
| ABOS | Acumen Pharmaceuticals, Inc. | $164.7M | — |
| TNYA | Tenaya Therapeutics, Inc. | $164.1M |
| — |
| BCAB | BioAtla, Inc. | $207.7M | — |
